Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

Data shows a 73% one-year survival rate for metastatic uveal melanoma patients treated in two Phase I studies of IMCgp100

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer and infectious diseases, today announces durable tumour responses and strong overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma.